Bictegravir/lenacapavir

BIXLENVO SUNLENCA STARTER PACK is a co-packaged product containing BIXLENVO and SUNLENCA tablets and is indicated for the initiation of BIXLENVO, a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO.

BIXLENVO is a fixed dose combination of the antiretroviral drugs bictegravir (BIC) and lenacapavir (LEN). SUNLENCA is the antiretroviral drug LEN.

Recommended Dosage: Two-day initiation regimen of BIXLENVO plus oral SUNLENCA ®, followed by a maintenance regimen of BIXLENVO. Tablets may be taken with or without food. Treatment Time Dosage: Initiation Day 1 BIXLENVO 75 mg/50 mg (1 tablet) orally and SUNLENCA 600 mg orally (2 × 300 mg tablets) Day 2 BIXLENVO 75 mg/50 mg (1 tablet) orally and SUNLENCA 600 mg orally (2 × 300 mg tablets) Dosage: Maintenance Day 3 and thereafter BIXLENVO 75 mg/50 mg (1 tablet) orally once daily Missed dose: Patients should take missed initiation or maintenance doses as soon as possible. If more than 7 days have elapsed since the last maintenance dose, restart initiation dosage regimen from Day 1, if clinically appropriate to continue BIXLENVO SUNLENCA STARTER PACK.

Concomitant administration of BIXLENVO is contraindicated with: dofetilide due to the potential for increased dofetilide plasma concentrations and associated serious and/or life-threatening events. strong CYP3A inducers due to decreased plasma concentrations of BIC and LEN, which may result in the loss of therapeutic effect and development of resistance to BIXLENVO. Concomitant administration of BIXLENVO SUNLENCA STARTER PACK is contraindicated with: Dofetilide Strong CYP3A inducers.

Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions The concomitant use of BIXLENVO with certain other drugs may result in known or potentially significant drug interactions, some of which may lead to: Loss of therapeutic effect of BIXLENVO and possible development of resistance. Possible clinically significant adverse reactions from greater exposures of concomitant drugs. See Table 4 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations. Consider the potential for drug interactions prior to and during BIXLENVO therapy, review concomitant medications during BIXLENVO therapy, and monitor for the adverse reactions associated with the concomitant drugs.

Most common adverse reactions (incidence greater than or equal to 2%, all grades) are headache, nausea, and diarrhea.

Because BIXLENVO SUNLENCA STARTER PACK is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. Consult the Full Prescribing Information prior to and during treatment for important drug interactions.

Store BIXLENVO tablets and SUNLENCA tablets at 20 °C to 25 °C (68 °F to 77 °F), excursions permitted between 15 °C to 30 °C (59 °F to 86 °F). Dispense and store only in the original bottles to protect from moisture.